Answers are grounded in this paper and cite their sources.
Our study highlights distinct roles for B cells in CNS autoimmunity. Clinical benefit from anti-CD20 treatment may relate to inhibition of proinflammatory B cell APC function. In certain clinical settings, however, elimination of unactivated B cells, which participate in regulation of T cells and other APC, may be undesirable. Differences in immune responses to MOG protein and peptide may be important considerations when choosing an EAE model for testing novel B cell-targeting agents for MS.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: